about
The designer methcathinone analogs, mephedrone and methylone, are substrates for monoamine transporters in brain tissueEphenidine: A new psychoactive agent with ketamine-like NMDA receptor antagonist propertiesPharmacological Investigations of the Dissociative 'Legal Highs' Diphenidine, Methoxphenidine and Analogues.Analysis of psychoactive cathinones and tryptamines by electrospray ionization atmospheric pressure ion mobility time-of-flight mass spectrometry.Ribonucleotide and ribonucleoside determination by ambient pressure ion mobility spectrometry.AMT (3-(2-aminopropyl)indole) and 5-IT (5-(2-aminopropyl)indole): an analytical challenge and implications for forensic analysis.Analyses of second-generation 'legal highs' in the UK: initial findings.The naphyrone story: The alpha or beta-naphthyl isomer?Analytical characterization of three trifluoromethyl-substituted methcathinone isomers.From the street to the laboratory: analytical profiles of methoxetamine, 3-methoxyeticyclidine and 3-methoxyphencyclidine and their determination in three biological matrices.5-(2-Aminopropyl)indole (5-IT): a psychoactive substance used for recreational purposes is an inhibitor of human monoamine oxidase (MAO).Preparation and characterization of the 'research chemical' diphenidine, its pyrrolidine analogue, and their 2,2-diphenylethyl isomers.Test purchase, identification and synthesis of 2-amino-1-(4-bromo-2, 5-dimethoxyphenyl)ethan-1-one (bk-2C-B).N-Benzyl-5-methoxytryptamines as Potent Serotonin 5-HT2 Receptor Family Agonists and Comparison with a Series of Phenethylamine Analogues.First reported fatalities associated with the 'research chemical' 2-methoxydiphenidine.Test purchase, synthesis, and characterization of 2-methoxydiphenidine (MXP) and differentiation from its meta- and para-substituted isomers.Metabolism of the new psychoactive substances N,N-diallyltryptamine (DALT) and 5-methoxy-DALT and their detectability in urine by GC-MS, LC-MSn, and LC-HR-MS-MS.Syntheses and analytical characterizations of N-alkyl-arylcyclohexylamines.The new psychoactive substances 5-(2-aminopropyl)indole (5-IT) and 6-(2-aminopropyl)indole (6-IT) interact with monoamine transporters in brain tissue.Return of the lysergamides. Part I: Analytical and behavioural characterization of 1-propionyl-d-lysergic acid diethylamide (1P-LSD)Cytochrome P450 inhibition potential of new psychoactive substances of the tryptamine class.Test purchase, synthesis and characterization of 3-fluorophenmetrazine (3-FPM) and differentiation from its ortho- and para-substituted isomers.Synthesis, characterization and monoamine transporter activity of the new psychoactive substance mexedrone and its N-methoxy positional isomer, N-methoxymephedrone.Mitigation of post-traumatic stress symptoms by Cannabis resin: a review of the clinical and neurobiological evidence.Powerful cocaine-like actions of 3,4-methylenedioxypyrovalerone (MDPV), a principal constituent of psychoactive 'bath salts' productsReinforcing and neurochemical effects of the "bath salts" constituents 3,4-methylenedioxypyrovalerone (MDPV) and 3,4-methylenedioxy-N-methylcathinone (methylone) in male rats.Pharmacological examination of trifluoromethyl ring-substituted methcathinone analogsSynthesis, characterization, and monoamine transporter activity of the new psychoactive substance 3',4'-methylenedioxy-4-methylaminorex (MDMAR).Analytical characterization and pharmacological evaluation of the new psychoactive substance 4-fluoromethylphenidate (4F-MPH) and differentiation between the (±)-threo and (±)-erythro diastereomers.Analytical techniques for the determination of tryptamines and β-carbolines in plant matrices and in psychoactive beverages consumed during religious ceremonies and neo-shamanic urban practices.Syntheses, analytical and pharmacological characterizations of the 'legal high' 4-[1-(3-methoxyphenyl)cyclohexyl]morpholine (3-MeO-PCMo) and analogues.Return of the lysergamides. Part III: Analytical characterization of N6 -ethyl-6-norlysergic acid diethylamide (ETH-LAD) and 1-propionyl ETH-LAD (1P-ETH-LAD).Atypical dopamine efflux caused by 3,4-methylenedioxypyrovalerone (MDPV) via the human dopamine transporter.New Psychoactive Substances 3-Methoxyphencyclidine (3-MeO-PCP) and 3-Methoxyrolicyclidine (3-MeO-PCPy): Metabolic Fate Elucidated with Rat Urine and Human Liver Preparations and their Detectability in Urine by GC-MS, "LC-(High Resolution)-MSn" and "Analytical characterization of N,N-diallyltryptamine (DALT) and 16 ring-substituted derivatives.Analytical characterization of bioactive N-benzyl-substituted phenethylamines and 5-methoxytryptamines.Identification and characterization of an imidazolium by-product formed during the synthesis of 4-methylmethcathinone (mephedrone).The first reported fatality associated with the synthetic opioid 3,4-dichloro-N-[2-(dimethylamino)cyclohexyl]-N-methylbenzamide (U-47700) and implications for forensic analysis.Characterization of the synthesis of N,N-dimethyltryptamine by reductive amination using gas chromatography ion trap mass spectrometry.Phenothiazinium photosensitisers VII: novel substituted asymmetric N-benzylphenothiaziniums as photoantimicrobial agents.
P50
Q24615008-FF656299-62EF-4E3F-9BC5-8FC0E7A6B51FQ28820763-BD80134C-516A-4681-AF2D-2263EC3F599EQ30379705-9CE54F3E-7186-4E0A-AFD0-AA753D7BE58EQ33458723-32C2684A-A86A-45C2-B0F9-BAFD18B29BF4Q33967956-F0BA6081-2136-4CF3-B9E2-C2FC6EE14350Q34033885-993DCC3F-75B7-43D6-BDA9-6256F701E2AFQ34129831-7D5A2138-0192-4291-9D43-0DB8293B2792Q34141130-34611FA0-87BE-4C14-9767-D4AE85E70E11Q34169500-5CFC9F55-CDCF-49A1-940D-3FA5B4399497Q34336819-CF67FCE3-3583-4A9D-817A-E4803A736EBBQ34377010-7391730B-AA01-4E1C-9D38-2452C1D2D781Q34430008-3095D491-865E-455B-90A2-BC9DE13B853FQ34431632-F4B2330B-3571-487E-B3D4-6754F375874AQ34455931-DBF14F00-3237-413C-8D27-67F5B9A5B86CQ34463746-66DD7917-5C28-4E1B-A605-3EF5E9C80051Q34471630-6604EB16-F76B-4A54-978D-7429AA86E35EQ34490537-A85031C7-2CAB-48B8-93B4-5421CFE41984Q34493655-FB4270A6-0652-4A34-A912-047742A71BA8Q34493739-0E628E4C-3B09-45A1-96DC-01ED35756AF0Q34497649-5BE07177-13E4-4FD0-8C38-73586270CC0DQ34502785-E0912B2F-6127-4934-BD53-927EA17CC751Q34510784-92793E31-5B29-4FF1-81C2-BDC39CD17793Q34537347-0966795B-FC6D-4489-A1F2-7A9B2E3F0309Q34639648-03FC5F60-E0B1-4C7C-8EC2-34AA9D1A880CQ36610017-6B5173F2-74A2-492F-A076-6FF3F29E4342Q36633551-9E35D2A3-E089-452C-A221-6AAFCB0C1078Q36851442-18D77B6E-3A30-45A7-9FA1-272D44B006ABQ37673496-5EF3274B-C206-48CE-AF06-DFE7D0ACE07BQ37735980-75274DBE-C0C7-4235-8EB7-83F69157BB2DQ38009283-57F31C9F-80D8-4E65-A538-C5CB3C90D3CEQ38781226-6819F285-EA6C-4EB3-83C0-9FEF66D2DD63Q38877013-1B24D18B-B773-4056-9834-5BC0CFAE62B2Q38978095-970D6184-F9BC-4916-8E98-5D11B50B3972Q39272650-F91C2361-7443-4E86-B902-36D0414F9CF0Q39834312-1E275E28-3F62-4B0F-BDE8-7C7D4B41367EQ40694962-CF07C243-AE38-412F-AAFF-94594AE684E2Q41109306-BA1894EC-D232-460D-9876-017E0A9F614EQ42696631-E91350C2-97E2-4FFD-8EFD-E7AF84CF866FQ42963079-5947EF30-1CA9-47C3-98EC-8A4F1A595B7BQ43128929-1A884C34-B46A-4653-8DF2-2374F81DC4B8
P50
description
farmacoloog
@nl
hulumtues
@sq
researcher
@en
ricercatore
@it
հետազոտող
@hy
name
Simon D. Brandt
@ast
Simon D. Brandt
@de
Simon D. Brandt
@en
Simon D. Brandt
@es
Simon D. Brandt
@nl
Simon D. Brandt
@sl
type
label
Simon D. Brandt
@ast
Simon D. Brandt
@de
Simon D. Brandt
@en
Simon D. Brandt
@es
Simon D. Brandt
@nl
Simon D. Brandt
@sl
prefLabel
Simon D. Brandt
@ast
Simon D. Brandt
@de
Simon D. Brandt
@en
Simon D. Brandt
@es
Simon D. Brandt
@nl
Simon D. Brandt
@sl
P227
P1153
7202305906
P21
P214
4976152988209712790009
P227
1161368280
P31
P496
0000-0001-8632-5372
P734
P7859
lccn-n2019185120